Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
|
|
|
5.
|
|
|
|
6.
|
|
|
|
7.
|
|
|
|
8.
|
|
|
|
9.
|
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. [electronic resource] by
- Laird, A Douglas
- Christensen, Jmes G
- Li, Guangmin
- Carver, Jeremy
- Smith, Kimberly
- Xin, Xiaohua
- Moss, Katherine G
- Louie, Sharianne G
- Mendel, Dirk B
- Cherrington, Julie M
Producer: 20020506
In:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology vol. 16
Availability: No items available.
|
|
|
10.
|
Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. [electronic resource] by
- Tolaney, Sara M
- Nechushtan, Hovav
- Ron, Ilan-Gil
- Schöffski, Patrick
- Awada, Ahmad
- Yasenchak, Chris A
- Laird, A Douglas
- O'Keeffe, Bridget
- Shapiro, Geoffrey I
- Winer, Eric P
Producer: 20171207
In:
Breast cancer research and treatment vol. 160
Availability: No items available.
|
|
|
11.
|
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. [electronic resource] by
- Jänne, Pasi A
- Cohen, Roger B
- Laird, A Douglas
- Macé, Sandrine
- Engelman, Jeffrey A
- Ruiz-Soto, Rodrigo
- Rockich, Kevin
- Xu, Jianbo
- Shapiro, Geoffrey I
- Martinez, Pablo
- Felip, Enriqueta
Producer: 20141021
In:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 9
Availability: No items available.
|
|
|
12.
|
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. [electronic resource] by
- Papadopoulos, Kyriakos P
- Tabernero, Josep
- Markman, Ben
- Patnaik, Amita
- Tolcher, Anthony W
- Baselga, José
- Shi, Weiliang
- Egile, Coumaran
- Ruiz-Soto, Rodrigo
- Laird, A Douglas
- Miles, Dale
- Lorusso, Patricia M
Producer: 20150820
In:
Clinical cancer research : an official journal of the American Association for Cancer Research vol. 20
Availability: No items available.
|
|
|
13.
|
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. [electronic resource] by
- Wen, Patrick Y
- Omuro, Antonio
- Ahluwalia, Manmeet S
- Fathallah-Shaykh, Hassan M
- Mohile, Nimish
- Lager, Joanne J
- Laird, A Douglas
- Tang, Jiali
- Jiang, Jason
- Egile, Coumaran
- Cloughesy, Timothy F
Producer: 20160511
In:
Neuro-oncology vol. 17
Availability: No items available.
|
|
|
14.
|
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. [electronic resource] by
- Shapiro, Geoffrey I
- Rodon, Jordi
- Bedell, Cynthia
- Kwak, Eunice L
- Baselga, Jose
- Braña, Irene
- Pandya, Shuchi S
- Scheffold, Christian
- Laird, A Douglas
- Nguyen, Linh T
- Xu, Yi
- Egile, Coumaran
- Edelman, Gerald
Producer: 20140818
In:
Clinical cancer research : an official journal of the American Association for Cancer Research vol. 20
Availability: No items available.
|
|
|
15.
|
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. [electronic resource] by
- Jabbour, Elias
- Gökbuget, Nicola
- Advani, Anjali
- Stelljes, Matthias
- Stock, Wendy
- Liedtke, Michaela
- Martinelli, Giovanni
- O'Brien, Susan
- Wang, Tao
- Laird, A Douglas
- Vandendries, Erik
- Neuhof, Alexander
- Nguyen, Kevin
- Dakappagari, Naveen
- DeAngelo, Daniel J
- Kantarjian, Hagop
Producer: 20200714
In:
Leukemia research vol. 88
Availability: No items available.
|
|
|
16.
|
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. [electronic resource] by
- DeAngelo, Daniel J
- Stock, Wendy
- Stein, Anthony S
- Shustov, Andrei
- Liedtke, Michaela
- Schiffer, Charles A
- Vandendries, Erik
- Liau, Katherine
- Ananthakrishnan, Revathi
- Boni, Joseph
- Laird, A Douglas
- Fostvedt, Luke
- Kantarjian, Hagop M
- Advani, Anjali S
Publication details: Blood advances Jun 2017
In:
Blood advances vol. 1
Availability: No items available.
|
|
|
17.
|
A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. [electronic resource] by
- Patel, Neela
- Sun, Li
- Moshinsky, Deborah
- Chen, Hui
- Leahy, Kathleen M
- Le, Phuong
- Moss, Katherine G
- Wang, Xueyan
- Rice, Audie
- Tam, Danny
- Laird, A Douglas
- Yu, Xiaoming
- Zhang, Qingling
- Tang, Cho
- McMahon, Gerald
- Howlett, Anthony
Producer: 20031003
In:
The Journal of pharmacology and experimental therapeutics vol. 306
Availability: No items available.
|
|
|
18.
|
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. [electronic resource] by
- Savona, Michael R
- Pollyea, Daniel A
- Stock, Wendy
- Oehler, Vivian G
- Schroeder, Mark A
- Lancet, Jeffrey
- McCloskey, James
- Kantarjian, Hagop M
- Ma, Weidong Wendy
- Shaik, M Naveed
- Laird, A Douglas
- Zeremski, Mirjana
- O'Connell, Ashleigh
- Chan, Geoffrey
- Cortes, Jorge E
Producer: 20191220
In:
Clinical cancer research : an official journal of the American Association for Cancer Research vol. 24
Availability: No items available.
|
|
|
19.
|
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. [electronic resource] by
- Cortes, Jorge E
- Heidel, Florian H
- Hellmann, Andrzej
- Fiedler, Walter
- Smith, B Douglas
- Robak, Tadeusz
- Montesinos, Pau
- Pollyea, Daniel A
- DesJardins, Pierre
- Ottmann, Oliver
- Ma, Weidong Wendy
- Shaik, M Naveed
- Laird, A Douglas
- Zeremski, Mirjana
- O'Connell, Ashleigh
- Chan, Geoffrey
- Heuser, Michael
Producer: 20190520
In:
Leukemia vol. 33
Availability: No items available.
|
|
|
20.
|
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. [electronic resource] by
- Yakes, F Michael
- Chen, Jason
- Tan, Jenny
- Yamaguchi, Kyoko
- Shi, Yongchang
- Yu, Peiwen
- Qian, Fawn
- Chu, Felix
- Bentzien, Frauke
- Cancilla, Belinda
- Orf, Jessica
- You, Andrew
- Laird, A Douglas
- Engst, Stefan
- Lee, Lillian
- Lesch, Justin
- Chou, Yu-Chien
- Joly, Alison H
Producer: 20120511
In:
Molecular cancer therapeutics vol. 10
Availability: No items available.
|